Get the Daily Brief
Latest Biotech News
Lab-Grown Beef Advances with Thicker, More Realistic Muscle Tissue
Researchers led by ETH Professor Ori Bar-Nur have successfully cultivated thicker, more anatomically realistic beef muscle tissue in laboratory settings. While official human consumption awaits...
AI-Powered Gene Set Analysis Tool Reduces Errors
Scientists at the U.S. National Library of Medicine developed GeneAgent, an artificial intelligence tool leveraging large language models (LLMs) with autonomous self-verification against...
Advances in Microbe-Based Therapeutics Controlled via Ingestible Capsules
Researchers have integrated engineered microbes with optoelectronic devices and smartphone interfaces to create the first fully controllable ingestible therapeutic platform. This system enables...
Novo Nordisk Cuts Sales Forecast Amid Obesity Drug Challenges and Names New CEO
Danish pharmaceutical leader Novo Nordisk slashed its 2025 sales growth forecast to 8%-14% from the prior 13%-21% range due to increasing competition from compounded semaglutide generics affecting...
Merck Launches $3 Billion Cost-Cutting Drive Amid Product Challenges
Merck & Co. announced a multiyear cost-reduction program aiming to save $3 billion annually by the end of 2027. The initiative will redirect resources from mature products to newer launches and...
Sarepta Cleared to Resume Duchenne Therapy Shipments for Ambulatory Patients
Following FDA investigations into safety concerns, Sarepta Therapeutics received clearance to recommence shipments of its gene therapy Elevidys for ambulatory Duchenne muscular dystrophy patients....
GeneDx Raises Revenue Forecast Amid Strong Genomic Testing Growth
GeneDx has upgraded its 2025 revenue guidance following robust second-quarter results, driven by a 49% year-over-year revenue increase. The genetic diagnostics firm saw whole-exome and...
GSK and Hengrui Ink $12.5 Billion Collaboration on Respiratory and Oncology Pipeline
GlaxoSmithKline has entered into a wide-ranging collaboration with Jiangsu Hengrui Pharmaceuticals valued at up to $12.5 billion, which includes an upfront payment of $500 million. The deal grants...
Celcuity Reports Breakthrough Phase III Data in Breast Cancer, Shares Surge
Minneapolis-based Celcuity announced positive topline results from its phase III Viktoria-1 trial evaluating gedatolisib combined with endocrine therapies in advanced HR+, HER2-, PIK3CA wild-type...
Advances in CRISPR and Genome Editing Highlighted in GEN Virtual Summit
The GEN ’s “The State of CRISPR & Genome Editing” virtual summit, broadcast June 11, 2025, featured talks from leading researchers covering novel genome editing innovations. Highlights include...
AI and Computational Innovations Boost Biotech Research and Drug Development
Multiple reports detail AI's growing role in biotech. NIH researchers unveiled GeneAgent, an AI agent reducing errors in gene-set analysis via database verification. Stanford scientists developed...
Novo Nordisk Cuts 2025 Forecast Amid Semaglutide Competition; Names New CEO
Novo Nordisk revised its 2025 sales growth projection downward to 8%-14%, from an earlier 13%-21% estimate, citing increasing competition from compounded versions of its obesity drug Wegovy and...
Apellis’ Empaveli Gains FDA Approval for Rare Kidney Conditions
Apellis Pharmaceuticals secured FDA approval for a supplemental new drug application expanding the use of its complement C3 inhibitor pegcetacoplan (Empaveli) to treat complement 3 glomerulopathy...
Merck’s $3B Cost-Cutting Push Amid Patent Losses
Merck & Co. revealed a sweeping initiative to cut costs by $3 billion annually by 2027, reallocating resources from mature products towards new drugs and experimental medicines. The effort aims to...
Novo Nordisk Downgrades Outlook Amid Obesity Drug Competition
Novo Nordisk lowered its full-year sales forecast for 2025 to 8-14% growth, down from the earlier 13-21% estimate, citing ongoing challenges from cheaper knockoff versions of its obesity drug...
Sarepta Cleared to Resume Duchenne Therapy Shipments
The FDA reversed a recent decision and authorized Sarepta Therapeutics to resume shipping its gene therapy Elevidys to ambulatory patients with Duchenne muscular dystrophy after concluding a...
Celcuity’s Breast Cancer Combo Surges With Phase III Success
Minneapolis-based Celcuity reported positive topline results from its phase III Viktoria-1 trial evaluating gedatolisib-based combinations for hormone receptor-positive, HER2-negative breast...
GSK’s $12.5B Deal with Hengrui for COPD and More
GlaxoSmithKline finalized a multi-billion dollar licensing agreement with Jiangsu Hengrui Pharmaceuticals granting rights to the potential best-in-class phosphodiesterase inhibitor HRS-9821 for...
Radiopharmaceutical Startup Artbio Raises $132M
European radiopharmaceutical company Artbio Therapeutics secured $132 million in Series B funding to advance its prostate cancer radioligand program into phase 2 clinical trials and expand its...
AI in Pharma: Sanofi CEO Advocates for AI in Decision-Making
Sanofi CEO Paul Hudson stressed at Davos the value of AI in drug development decisions, highlighting that AI agents provide dispassionate recommendations without career bias. The company uses AI...